Arcturus Therapeutics HoldingsARCT
Recorded

Arcturus Therapeutics Holdings 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration51 minParticipants15

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please stand by. Your meeting is about to begin. Hello, and welcome everyone joining today's Arcturus Therapeutics Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. To register to ask a question at any time, please press star one on your telephone keypad. Please note, this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations, and Marketing.

Neda SafarzadehVP of Investor Relations, Public Relations, and Marketing

Please go ahead. Thank you, operator.

Neda SafarzadehVP of Investor Relations, Public Relations, and Marketing

Good afternoon, and welcome to Arcturus Therapeutics Quarterly Financial Update and Pipeline Progress Call. Today's call will be led by Joe Payne, our President and CEO, and Dennis Mulroy, our Chief Financial Officer. Dr. Patribikula, our CSO and COO, and Dr. Alan Cohen, our Chief Medical Officer, will join them for the Q&A session. Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by this statement.

Neda SafarzadehVP of Investor Relations, Public Relations, and Marketing

Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factor section in our most recent Form 10-K and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements. With that, I will now turn the call over to Joe.

Joe PaynePresident and CEO

Thank you, Neda. Good afternoon, everyone, and thank you for joining us today. The third quarter was an important period for Arcturus as we continued to advance our key clinical programs, introduced our next-generation LUNAR 2.0 delivery platform, and expanded our pipeline of mRNA therapeutics. I'd like to begin with our liver therapeutics franchise, where we believe we are entering a new exciting phase of development. In September, we presented encouraging phase II data from ARCT-810 in patients with ornithine transcarbamylase, or OTC, deficiency. At the 0.3 and 0.5 milligram per kilogram dose levels, ARCT-810 demonstrated meaningful biomarker activity, reducing and/or maintaining first morning fasting ammonia within the normal range, including during increased protein intake, and reducing glutamine levels in all participants, with the 0.5 milligram per kilogram dose achieving mean glutamine concentrations within the normal range during treatment, and was generally safe and well tolerated.

Joe PaynePresident and CEO

These results provide important clinical validation of our mRNA approach to liver therapeutics and contributed to the development of our next-generation OTC program called ARCT-2601. ARCT-2601 is particularly significant for Arcturus because it is the first mRNA therapeutic candidate utilizing our new LUNAR 2.0 delivery technology. Non-human primate models have consistently demonstrated strong translational predictivity for lipid nanoparticle-formulated RNA therapeutics. This is well documented. In non-human primates, we can measure human ornithine transcarbamylase expression. In this non-human primate model, we demonstrated a 38-fold improvement in potency using LUNAR 2.0 compared to the original LUNAR formulation that we used in ARCT-810. We believe this substantial improvement in delivery efficiency has the potential to enable lower and less frequent dosing and potentially broaden the range of diseases we can address with our mRNA therapeutics. We shared the LUNAR 2.0 data with the FDA.

Joe PaynePresident and CEO

Following favorable FDA feedback and clarity on the regulatory pathway from our Type C meeting in June, we now plan to initiate phase II dosing of ARCT-2601 next quarter. The amended protocol will evaluate patients with OTC deficiency ages 12 and older, and we expect top-line data in the second half of 2027. Central to our thesis is safe and effective delivery of mRNA. We work in the field of RNA therapeutics where delivery is everything, so you can understand why we are looking forward to seeing this first potential clinical top-line data for ARCT-2601, as this is the first opportunity to confirm how the 38-fold improvement we observed in non-human primates translates into patients. Beyond OTC deficiency, LUNAR 2.0 is enabling us to expand our liver therapeutics pipeline into additional genetic diseases, including phenylketonuria, or PKU, and gout.

Joe PaynePresident and CEO

For PKU, we are developing an investigational LUNAR 2.0-formulated mRNA therapy designed to enable the liver to produce functional PAH. This is the enzyme that is deficient in patients with PKU. Our objective is to restore PAH activity, improve phenylalanine metabolism, and ultimately address the underlying cause of the disease. We currently plan to submit an IND for this program in the second half of 2027. Turning now to our respiratory franchise. We continue to make progress with ARCT-032 in CF. Enrollment in cohort four of the phase II study has accelerated as we have activated additional clinical sites in Israel and Turkey. We expect enrollment to be completed by year-end, with full cohort four data planned for presentation in the second quarter of 2027.

Joe PaynePresident and CEO

Cohort four is evaluating 10 milligrams of ARCT-032 administered by inhalation for 12 weeks in up to 20 adults with cystic fibrosis, primarily class I CF subjects. We are also pleased with the continued support of Thermo Fisher Scientific for the ARCT-032 program. Under our collaboration, a decision to advance ARCT-032 into phase III would trigger significant contributions from Thermo Fisher, with that decision expected when top-line data is available before our planned phase II full data presentation. With the ongoing bolus of patients enrolling in Turkey and Israel, the data generated from these patients may be included to inform that decision. Thermo Fisher receives regular updates in accordance with our agreement, and per the agreement, the decision to advance ARCT-032 into phase III remains under Arcturus' control. During the quarter, we also continued to strengthen our broader technology capabilities and AI infrastructure.

Joe PaynePresident and CEO

We completed the acquisition of myNEO, adding AI-driven capabilities in antigen design, mRNA optimization, and target identification. We believe integrating these capabilities with our existing mRNA design and delivery expertise can accelerate pipeline development and create additional strategic opportunities, including oncology, given myNEO's seven years of experience expertly designing neoantigens. On the vaccine side of our business, KOSTAIVE, our self-amplifying mRNA COVID vaccine, continues to be commercialized in Japan through our partner Meiji for the 2026-2027 season. We also successfully completed the transfer of the marketing authorization holder rights for KOSTAIVE in both the European Union and the U.K. from CSL Seqirus to Arcturus. These transfers are an important step as we move toward executing commercial objectives for KOSTAIVE in 2027. We also recently published the results of our phase I study for our self-amplifying mRNA pandemic influenza vaccine in Nature Communications.

Joe PaynePresident and CEO

The study demonstrated immunological benefits compared with standard of care, a favorable safety profile, and the potential for a single-dose pandemic response. Taken together, we believe these developments in our vaccine enterprise demonstrate the breadth of our mRNA platform and the evolution of Arcturus. We now have important programs progressing across respiratory and liver therapeutics, a next-generation delivery technology with LUNAR 2.0, an expanding pipeline in genetic diseases, additional AI-enabled discovery capabilities through myNEO, and a commercial vaccine platform led with KOSTAIVE. Looking ahead, we have several important milestones approaching. We expect to complete enrollment in the ARCT-032 phase II study by year-end, present the full phase II CF data in the second quarter of 2027, initiate phase II dosing of ARCT-2601 in the first quarter of 2027, and report top-line ARCT-2601 data in the second half of 2027.

Joe PaynePresident and CEO

Our focus remains on disciplined execution and advancing the programs where we believe our technology can deliver meaningful differentiation in patients and long-term value for shareholders. With that, I'll turn the call over to Dennis to review our third quarter financial results.

Dennis MulroyCFO

Thanks, Joe, and good afternoon, everyone. Our press release issued earlier today includes financial statements for the three and nine months ended September 30, 2026, and provides a summary and analysis of year-over-year performance. Please also reference our Form 10-Q for more details on our financial performance. Cash and cash equivalents were $184.8 million as of September 30, 2026, and $230.9 million on December 31, 2025, for a decrease of $46.1 million during the first nine months of 2026. The decrease was primarily driven by cash used for ongoing clinical development activities, including the continued advancement of the company's cystic fibrosis and OTC deficiency programs, partially offset by $12 million payment received from CSL Seqirus under the termination and settlement agreement.

Dennis MulroyCFO

Revenue was $18.3 million and $23.3 million for the three and nine months ended September 30, 2026, compared to $17.2 million and $74.8 million in the comparable periods last year. The increase in revenue for the three-month period was primarily driven by the recognition of the $12 million termination payment and the remaining deferred revenue upon termination of the CSL Seqirus collaboration, under which the company regained strategic control of KOSTAIVE and its broader vaccine portfolios, partially offset by lower grant revenue. The decrease of the nine-month period was primarily attributable to revenue recognized under the CSL Seqirus collaboration prior to the termination and lower BARDA grant revenue. Research and development expenses were $17 million and $56 million for the three and nine months ended September 30, 2026, compared to $23.3 million and $87.7 million for the corresponding periods in 2025.

Dennis MulroyCFO

The decreases were primarily driven by reduced clinical and manufacturing activities, particularly across the LUNAR-COVID and BARDA programs, together with lower personnel and facility costs as the company continues to advance its highest priority programs while maintaining a disciplined approach to capital allocation. General and administrative expenses were $10.5 million and $30.9 million for the three and nine months ended September 30, 2026, compared with $10.4 million and $32.1 million in the comparable period last year. Overall, general and administrative expenses remained relatively consistent for the quarter, and the year-to-date decrease primarily driven by lower payroll and benefit costs and lower share-based compensation expense, all resulting with lower headcount and particularly offset by increased legal and professional fees.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day